DO-BO

What Will It Take to Keep Biotech Growing in Europe, Rainer Westermann?

In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Rainer Westermann, Chairman of the Life Sciences Acceleration Alliance (LSAA), to ask whether Europe can remain a globally competitive home for life sciences innovation — and what has to change for new therapies to reach patients.

Bringing an investor’s lens, Rainer explains why so many promising European companies scale in the US instead: the “valley of death” between great science and a viable business, the shortage of productive growth capital, the absence of a deep, liquid capital market, and the drag of long timelines, fragmented member-state systems, and cost-containment-first thinking. They also unpack the ripple effects of the US Most Favored Nation policy, the patent cliff, and why patients — who are also voters — belong at the center of the debate.

Related

Is the EU Joint Clinical Assessment just another administrative layer, or the start of a truly European HTA? In this MAP episode, Dr. Stefan Walzer talks with Dr. Oriol Solà-Morales, physician, health economist, founder and CEO of HITT and founding member of EUnetHTA, about what the first JCA reports reveal. Drawing on Spain’s shift from […]

AI is reshaping health economics and outcomes research (HEOR) – but where does it truly belong? In this MAP episode, Dr. Stefan Walzer talks with Haidong Feng, Associate Principal Scientist at Merck, about “human in the loop” versus “AI in the loop” and why the two complement rather than contradict each other. Haidong explains why […]

When the US benchmarks drug prices against other countries, the whole world feels it. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Brittany La Couture of Applied Policy, a health policy attorney with eight years at the Centers for Medicare & Medicaid Services, to unpack the US […]